<?xml version="1.0" encoding="UTF-8"?>
<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on January 26, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02915172</url>
  </required_header>
  <id_info>
    <org_study_id>2016-0323</org_study_id>
    <nct_id>NCT02915172</nct_id>
  </id_info>
  <brief_title>Lenvatinib and Capecitabine in Patients With Advanced Malignancies</brief_title>
  <official_title>A Phase I Trial of Lenvatinib (Multi-kinase Inhibitor) and Capecitabine (Anti-metabolite) in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are 2 phases in this study: Phase 1 (dose escalation) and Phase 2 (dose expansion).

      The goal of Phase 1 of this clinical research study is to find the highest tolerable dose of
      lenvatinib and Xeloda (capecitabine) that can be given to patients with advanced cancer. The
      goal of Phase 2 of this study is to learn if the dose of lenvatinib and capecitabine found
      in Phase 1 can help to control advanced cancer.

      The safety of this drug combination will be studied in both phases of the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Groups:

      If participant is are found to be eligible to take part in this study, they will be assigned
      to a study group based on when they join this study. Up to 4 groups of up to 18 participants
      will be enrolled in Phase 1 of the study, and up to 28 participants will be enrolled in
      Phase 2.

      If participant is enrolled in Phase 1, the dose of lenvatinib they receive will depend on
      when they join this study. The first group of participants will receive the lowest dose
      level of lenvatinib. Each new group will receive a higher dose of lenvatinib than the group
      before it, if no intolerable side effects were seen. This will continue until the highest
      tolerable dose of lenvatinib is found.

      If participant is enrolled in Phase 2, they will receive lenvatinib at the highest dose that
      was tolerated in Phase 1.

      All participants will receive the same dose of capecitabine.

      Study Drug Administration:

      Each study cycle is 21 days.

      Participant will take lenvatinib by mouth every day and capecitabine by mouth 2 times every
      day.

      Length of Study Participation:

      Participant may continue taking the study drugs for as long as the doctor thinks it is in
      their best interest. Participant will no longer be able to take the study drugs if the
      disease gets worse, if intolerable side effects occur, or if they are unable to follow study
      directions.

      Patient's participation on the study will be over after the end-of-study visit (described
      below).

      Study Visits:

      During Week 2 of Cycle 1:

        -  Participant will have a physical exam.

        -  Blood (about 3 teaspoons) will be drawn for routine tests.

        -  If participant is enrolled in Phase 2, they will have a tumor biopsy for biomarker
           testing.

        -  If participant is enrolled in Phase 2, blood (about 2 teaspoons) will be drawn for
           biomarker, CTC, and cfDNA testing.

      During Week 3 of Cycle 1, blood (about 3 teaspoons) will be drawn for routine tests.

      During Week 1 of Cycles 2 and beyond:

        -  Participant will have a physical exam.

        -  Blood (about 3 teaspoons) will be drawn for routine tests.

        -  If participant is enrolled in Phase 2, blood (about 2 teaspoons) will be drawn for
           biomarker, CTC, and cfDNA testing.

        -  If participant can become pregnant, blood (about 1 teaspoon) will be collected for a
           pregnancy test.

      During Weeks 2 and 3 of Cycles 2 and beyond, participant will be called by a member of the
      study staff and asked about any side effects they may have. This call should last about 5-10
      minutes.

      During Week 3 of Cycle 2 and then every even-numbered cycle after that (Cycles 4, 6, 8, and
      so on), participant will have a CT scan or MRI.

      End-of-Study Visit:

      After participant's last dose of study drug, they will have an end-of-study visit. At this
      visit, the following tests and procedures will be performed:

        -  Participant will have a physical exam.

        -  Blood (about 3 teaspoons) will be drawn for routine tests.

        -  Participant will have a CT scan or MRI to check the status of the disease.

        -  If participant can become pregnant, blood (about 1 teaspoon) or urine will be collected
           for a pregnancy test.

        -  If participant is enrolled in Phase 2, blood (about 2 teaspoons) will be drawn for
           biomarker, CTC, and cfDNA testing.

      This is an investigational study. Lenvatinib is FDA approved and commercially available for
      the treatment of certain types of thyroid cancer. Capecitabine is FDA approved and
      commercially available for the treatment of certain types of breast and colorectal cancers.
      It is considered investigational to use lenvatinib and capecitabine to treat advanced
      cancer.

      The study doctor can explain how the study drugs are designed to work.

      Up to 46 participants will be enrolled in this study. All will take part at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of Combination Treatment with Lenvatinib and Capecitabine in Advanced and/or Metastatic Cancer Refractory to Standard Treatment</measure>
    <time_frame>3 weeks</time_frame>
    <description>MTD defined by dose limiting toxicities (DLTs) that occur in the first cycle. DLT defined as any clinically grade 3 or 4 non-hematologic toxicity as defined in the NCI CTC v4.0,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumor Efficacy of Combination of Lenvatinib and Capecitabine in Breast Cancer and Solid Tumors with FGFR Abnormality</measure>
    <time_frame>42 days</time_frame>
    <description>Efficacy evaluation done using RECIST criteria version 1.1.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Advanced Cancer</condition>
  <condition>Malignant Neoplasm of Breast</condition>
  <condition>Malignant Neoplasms of Bone and Articular Cartilage</condition>
  <condition>Malignant Neoplasms of Digestive Organs</condition>
  <condition>Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System</condition>
  <condition>Malignant Neoplasms of Female Genital Organs</condition>
  <condition>Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites</condition>
  <condition>Malignant Neoplasms of Independent (Primary) Multiple Sites</condition>
  <condition>Malignant Neoplasms of Lip Oral Cavity and Pharynx</condition>
  <condition>Malignant Neoplasms of Male Genital Organs</condition>
  <condition>Malignant Neoplasms of Mesothelial and Soft Tissue</condition>
  <condition>Malignant Neoplasms of Respiratory and Intrathoracic Organs</condition>
  <condition>Malignant Neoplasms of Thyroid and Other Endocrine Glands</condition>
  <condition>Malignant Neoplasms of Urinary Tract</condition>
  <arm_group>
    <arm_group_label>Lenvatinib + Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1 Study Escalation: Group consists of participants with various solid tumors.
Dose of Lenvatinib received depends on when joining study. First group of participants receive lowest dose level of Lenvatinib. Each new group receives a higher dose of Lenvatinib than the group before it, if no intolerable side effects were seen. This continues until highest tolerable dose of Lenvatinib found.
All participants receive the same dose of Capecitabine.
Phase 2 Study Expansion: Group consists of participants with advanced breast cancer and any solid tumors with confirmed FGFR abnormalities.
Participants receive Lenvatinib at the highest dose that was tolerated in Dose Escalation Phase.
All participants receive the same dose of Capecitabine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Phase 1 Dose Escalation: Starting dose of Lenvatinib 10 mg by mouth once daily of a 21 day cycle.
Phase 2 Dose Expansion: Starting dose of Lenvatinib is maximum tolerated dose from Phase 1.</description>
    <arm_group_label>Lenvatinib + Capecitabine</arm_group_label>
    <other_name>E7080</other_name>
    <other_name>Lenvima</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Phase 1 Dose Escalation and Phase 2 Dose Expansion: Capecitabine 1000 mg/m2 twice daily by mouth on Days 1 - 14 of a 21 day cycle.</description>
    <arm_group_label>Lenvatinib + Capecitabine</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with a histologically and/or cytologically confirmed solid tumor who are
             resistant / refractory to approved therapies or for whom no curative therapies are
             available.

          2. All previous treatment (including surgery, radiotherapy and systemic anti-neoplastic
             therapy) must have been completed at least three weeks prior to study entry and any
             acute toxicities must have resolved.

          3. Aged &gt;/= 18 years.

          4. Eastern Cooperative Oncology Group (ECOG) performance status score of &lt;/= 2.

          5. Written informed consent prior to any study specific screening procedures with the
             understanding that the patient may withdraw consent at any time without prejudice.

          6. Willing and able to comply with the protocol guidelines for the duration of the
             study.

        Exclusion Criteria:

          1. Unstable metastases to the central nervous system (CNS).

          2. Any of the following laboratory parameters: a) hemoglobin &lt; 9 g/dL (5.6 mmol/L); b)
             neutrophils &lt;1.5 x 109/L; c) platelets &lt;100 x 109/L; d) serum bilirubin &gt;25 Âµmol/L
             (1.5 mg/dL); e) liver function tests with values &gt;3 x upper limit of normal (ULN) f)
             serum creatinine &gt;1.5 x ULN or creatinine clearance &lt; 60 mL/minute

          3. Positive history of HIV, active hepatitis B or active hepatitis C or
             severe/uncontrolled intercurrent illness or infection

          4. Centrally located non-small cell lung cancers and squamous cell lung cancers

          5. Clinically significant cardiac impairment or unstable ischemic heart disease
             including a myocardial infarction within six months of study start

          6. Patients with marked Baseline prolongation of QT/QTc interval (QTc interval &gt; 450
             msec for males or &gt; 470 msec for females) using the Fridericia method for QTc
             analysis

          7. Bleeding or thrombotic disorders, or using therapeutic dosages of anticoagulants,
             such as warfarin. Occasional use of NSAIDs and antiplatelet agents such as aspirin,
             clopidogrel, aggrenox and dipyridamole are not considered exclusionary if taken &lt;7
             days per 28 days. However, if the patient requires chronic use (&gt;/=7 days out of 28
             days) of full doses of aspirin or NSAIDs then the patient is excluded.

          8. Requirement for chronic use of full dose aspirin or non-steroidal anti-inflammatory
             drugs (NSAIDs)

          9. Poorly controlled hypertension (defined as requiring changes in any hypertensive
             regimen within 1 week of study entry) or patients diagnosed with hypertension based
             on repeat blood pressure measurements of &gt;160/90 mmHg at Screening

         10. Proteinuria &gt; 1+ on urine dipstick testing or 30 mg/dL

         11. A history of gastrointestinal malabsorption or having undergone surgery requiring
             gastrointestinal anastomoses within four weeks of starting therapy or who have not
             recovered from major surgery within three weeks of starting therapy

         12. History of alcoholism, drug addiction, or any psychiatric or psychological condition
             which, in the opinion of the Investigator, would impair study compliance.

         13. Any treatment with investigational drugs within 30 days before the start of the study

         14. Previous treatment with E7080

         15. Women who are pregnant or breast-feeding; women of childbearing potential with a
             positive pregnancy test at Screening or no pregnancy test. Women of childbearing
             potential unless (1) surgically sterile or (2) using adequate measures of
             contraception (including two forms of contraception, one of which must be a barrier
             method) in the opinion of the Investigator. Perimenopausal women must be amenorrheic
             for at least 12 months to be considered of non-childbearing potential.

         16. Fertile males with female partners who are not willing to use contraception or whose
             female partners are not using adequate contraceptive protection

         17. Legal incapacity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David S. Hong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David S. Hong, MD</last_name>
    <phone>713-563-1930</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 23, 2016</lastchanged_date>
  <firstreceived_date>September 23, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Cancer</keyword>
  <keyword>Malignant neoplasm of breast</keyword>
  <keyword>Malignant neoplasms of bone and articular cartilage</keyword>
  <keyword>Malignant neoplasms of digestive organs</keyword>
  <keyword>Malignant neoplasms of eye brain and other parts of central nervous system</keyword>
  <keyword>Malignant neoplasms of female genital organs</keyword>
  <keyword>Malignant neoplasms of ill-defined secondary and unspecified sites</keyword>
  <keyword>Malignant neoplasms of independent (primary) multiple sites</keyword>
  <keyword>Malignant neoplasms of lip oral cavity and pharynx</keyword>
  <keyword>Malignant neoplasms of male genital organs</keyword>
  <keyword>Malignant neoplasms of mesothelial and soft tissue</keyword>
  <keyword>Malignant neoplasms of respiratory and intrathoracic organs</keyword>
  <keyword>Malignant neoplasms of thyroid and other endocrine glands</keyword>
  <keyword>Malignant neoplasms of urinary tract</keyword>
  <keyword>Lenvatinib</keyword>
  <keyword>E7080</keyword>
  <keyword>Lenvima</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Xeloda</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Urologic Neoplasms</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Cartilage Diseases</mesh_term>
    <mesh_term>Soft Tissue Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Fibrous Tissue</mesh_term>
    <mesh_term>Lip Neoplasms</mesh_term>
    <mesh_term>Genital Neoplasms, Male</mesh_term>
    <mesh_term>Eye Neoplasms</mesh_term>
    <mesh_term>Genital Neoplasms, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
